Drug Trial Radar · NCT01836458
A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
Last checked: Nov 19, 2026Latest source record: Oct 31, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Jan 2014
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Apr 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609
Conditions
- Malaria
Interventions
KAE609Drug
Patients will receive KAE609 single dose at a different dose level in each cohort.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimum Inhibitory Concentration (MIC) of KAE609Time frame: Up to Day 8 after a single dose of KAE609
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis Investigative Site
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.